Survival

Survival depends on many different factors. It depends on your individual condition, type of neuroendocrine tumour (NET), treatment and level of fitness. So no one can tell you exactly how long you will live. 

These are general statistics based on large groups of people. Remember, they can’t tell you what will happen in your individual case.

Your doctor can give you more information about your own outlook (prognosis).

You can also talk about this with the Cancer Research UK nurses on freephone 0808 800 4040, from 9am to 5pm, Monday to Friday.

About these statistics

The terms 1 year survival and 5 year survival don't mean that you will only live for 1 or 5 years.

The Office for National Statistics (ONS) and researchers collect information. They watch what happens to people with cancer in the years after their diagnosis. 5 years is a common time point to measure survival. But some people live much longer than this.

5 year survival is the number of people who have not died from their cancer within 5 years after diagnosis.

Where this information comes from

In the UK, no statistics are available for the survival of the different types of stomach NETs. The statistics presented here are international and might not accurately reflect UK statistics. They are gathered from various sources, including the opinions and experience of the experts who check our information.

We have information about the overall survival of people with stomach cancer. Remember to click back to return to the neuroendocrine section.

Survival for all types of stomach NET

1 year survival

The 1 year survival statistics below are for all types of stomach NETs in the UK.

  • Around 75 out of 100 people (around 75%) survive for 1 year after their diagnosis

5 year survival

There are no UK-wide 5 year survival statistics available for all types of stomach NETs. The 5 year survival statistics below are from a European study. Please be aware that due to differences in health care systems, data collection and the population, these figures may not be a true picture of survival in the UK.

  • Almost 60 out of 100 people (almost 60%) survive for 5 years after their diagnosis

Types of stomach NET

There are 3 types of stomach NETs:

  • type 1 (this is the most common type)
  • type 2
  • type 3

Survival for type 1 stomach NETs

Almost 100 out of 100 people (almost 100%) with a type 1 stomach neuroendocrine tumour survive for 5 years or more.

Survival for type 2 stomach NETs

Between 60 and 75 out of 100 people (between 60 and 75%) with a type 2 stomach neuroendocrine tumour survive for 5 years or more.

Survival for type 3 stomach NETs

75 out of 100 people (75%) who have a type 3 stomach NET, and have had extensive surgery to remove the tumour, survive for 5 years or more.

Stomach NETs that have spread to a distant part of the body can be more difficult to treat.

What affects survival?

Survival depends on many factors. It depends on the stage and grade of the NET when it was diagnosed. The stage describes the size of the tumour and whether it has spread. The grade means how abnormal the cells look under a microscope. 

Another factor is how well you are overall.

Last reviewed: 
24 Jun 2022
Next review due: 
24 Jun 2025
  • Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project
    J Maartaen Van de Zwan and others
    European Journal of Cancer Volume 49, Issue 11 July 2013, Pages 2565-2578

  • Gastric Neuroendocrine Tumours
    DA Crosby and others
    Digestive Surgery, 2012. Vol 29

  • Classification, clinicopathologic features and treatment of gastric neuroendocrine tumours
    L Ting – Ting and others
    World Journal of Gastroenterology, 2014. Vol 20, Issue 1

  • ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms
    G Delle Fave and others
    Neuroendocrinology, 2012. Vol 95

  • Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015
    T Genus and others
    British Journal of Cancer (2019) Volume 121, pages 966–972

  • The information on this page is based on literature searches and specialist checking. We used many references and there are too many to list here. Please contact patientinformation@cancer.org.uk with details of the particular issue you are interested in if you need additional references for this information.

Related links